These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29534146)

  • 1. PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
    Chang G; Zheng J; Xiao W; Chang S; Wei Q; Wu H; Tao Y; Yang G; Xie B; Lan X; Wang Y; Yu D; Hu L; Xie Y; Bu W; Kong Y; Dai B; Hou J; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):399-407. PubMed ID: 29534146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
    Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
    Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.
    Dai B; Zhao XF; Hagner P; Shapiro P; Mazan-Mamczarz K; Zhao S; Natkunam Y; Gartenhaus RB
    Cancer Res; 2009 Oct; 69(19):7835-43. PubMed ID: 19789340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.
    Nandi S; Reinert LS; Hachem A; Mazan-Mamczarz K; Hagner P; He H; Gartenhaus RB
    Oncogene; 2007 Apr; 26(16):2283-9. PubMed ID: 17016429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
    Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
    Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
    Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
    Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
    Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma.
    Jiang L; Xu Y; Zeng X; Fang J; Morse HC; Zhou JX
    Oncotarget; 2015 Oct; 6(31):31191-202. PubMed ID: 26435477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus.
    von Hahn T; Schulze A; Chicano Wust I; Heidrich B; Becker T; Steinmann E; Helfritz FA; Rohrmann K; Urban S; Manns MP; Pietschmann T; Ciesek S
    PLoS One; 2011; 6(9):e24142. PubMed ID: 21909416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.
    Yang W; Li Y; Li P; Wang L
    Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators.
    Cerda SR; Mustafi R; Little H; Cohen G; Khare S; Moore C; Majumder P; Bissonnette M
    Oncogene; 2006 May; 25(22):3123-38. PubMed ID: 16434969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis.
    Peng C; Sun C; Wang N; He Y; Xu J; Deng Y; Gao L; Zhong J; Xiong X; Liu L
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31527063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of 2-12alkyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione(DMDD)on diffuse large B lymphoma and its mechanism].
    Hong K; Jiang PR; Ke RJ; Ying JH; Zhang XY; Chen JY
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2019 Jul; 35(4):312-316. PubMed ID: 31701713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.